Recovery is fairly straightforward: typically a day or so of redness and mild swelling, occasionally accompanied by a sandpaper-like texture for a few days as the epidermis renews
Reduced Glutathione (GSH) This is the active form of glutathione and is often used in supplements
The OP dichlorvos, considered an estrogenic EDC, also mimics androgen function in LNCaP cells, increasing AR expression and its translocation to the nucleus [288]
Vitamin C is consumed in Glutathione to help with the depletion of antioxidant properties
The complete side effect frequency breakdown from Phase 2 trials: Very Common (20%+ of patients at 12mg dose) Nausea: 28% Typically mild to moderate, peaks weeks 4-8, usually resolves by week 12 Diarrhea: 24% Usually transient (1-3 weeks), rarely severe Constipation: 21% Paradoxically coexists with diarrhea in different patients Common (10-20% of patients) Vomiting: 17% Decreased appetite: 16% (beyond therapeutic effect) Injection site reactions: 14% Fatigue: 13% Dyspepsia (indigestion): 12% Headache: 11% Uncommon (2-10% of patients) Abdominal pain: 8% Dizziness: 7% Gastroesophageal reflux: 6% Hypoglycemia in diabetics on other medications: 5% Increased heart rate (average 2-4 bpm): 4% Hair thinning/loss: 3% (typically temporary) Rare but Serious (Under 2%) Pancreatitis: 0.3% (3 cases out of 1,032 patients, all resolved with discontinuation) Gallbladder events: 1.4% (expected with rapid weight loss regardless of method) Acute kidney injury: 0.7% (all cases associated with severe dehydration) KEY TAKEAWAY: About 30% experience meaningful nausea in the first 4-8 weeks
Consistency in dosing and following your personalized protocol is key to seeing results over time
